A National Coverage Decision would be CMS’s route to limited but equitable aducanumab coverage

Questions about reimbursement and market access are on everyone’s mind now that aducanumab is approved for Alzheimer’s disease, but there’s a long road ahead to figure out how the drug and its related medical expenses will be covered, and for which patients.

Five reimbursement consultants interviewed by BioCentury agree the coverage debate will likely end in a National Coverage Decision from Centers for Medicare and Medicaid Services (CMS), but that will take months if not years to implement...